Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$4.34
-0.5%
$4.40
$1.34
$5.15
$608.94M0.761.06 million shs1.09 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.95
-0.5%
$1.92
$0.65
$2.53
$870.62M1.071.87 million shs1.85 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.87
-1.3%
$42.94
$23.57
$60.08
$1.31B0.47340,092 shs200,512 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$18.55
+0.4%
$20.79
$8.59
$25.59
$1.64B0.381.62 million shs2.17 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-0.46%+0.93%-3.98%+18.58%+201.39%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-0.51%+3.72%-12.56%+25.00%+191.04%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.27%-2.39%-7.27%-38.98%+28.98%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+0.38%+4.86%-8.30%-21.56%+85.69%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$4.34
-0.5%
$4.40
$1.34
$5.15
$608.94M0.761.06 million shs1.09 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$1.95
-0.5%
$1.92
$0.65
$2.53
$870.62M1.071.87 million shs1.85 million shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$31.87
-1.3%
$42.94
$23.57
$60.08
$1.31B0.47340,092 shs200,512 shs
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$18.55
+0.4%
$20.79
$8.59
$25.59
$1.64B0.381.62 million shs2.17 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-0.46%+0.93%-3.98%+18.58%+201.39%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-0.51%+3.72%-12.56%+25.00%+191.04%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
-1.27%-2.39%-7.27%-38.98%+28.98%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
+0.38%+4.86%-8.30%-21.56%+85.69%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.13
Buy$11.50164.98% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.33
Hold$4.55133.33% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.00
Hold$42.5033.35% Upside
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
2.92
Moderate Buy$42.55129.36% Upside

Current Analyst Ratings Breakdown

Latest ACRS, LXRX, SNDX, and PAHC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/15/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeBuy (B-)Hold (C+)
6/12/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy
6/12/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy$40.00
6/3/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy$40.00
6/2/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Initiated CoverageOutperform$13.00
6/1/2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
UpgradeStrong-Buy
5/22/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Reiterated RatingBuy$40.00
5/21/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
DowngradeStrong-BuyHold
5/14/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Lower Price TargetNeutral$62.00 ➝ $44.00
5/13/2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
Lower Price TargetBuy$38.00 ➝ $37.00
5/11/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Boost Price TargetBuy$2.30 ➝ $3.10
(Data available from 6/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$8.37M72.44N/AN/A$0.85 per share5.11
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M17.39N/AN/A$0.30 per share6.50
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.50B0.86$3.23 per share9.87$7.05 per share4.52
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
$217.17M7.57N/AN/A$0.74 per share25.07
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$64.92M-$0.56N/AN/AN/A-832.58%-55.89%-38.49%8/6/2026 (Estimated)
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$48.26M$2.3313.689.570.496.35%37.14%8.57%6/30/2026 (Confirmed)
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$285.42M-$2.79N/AN/AN/A-111.88%-256.65%-45.25%8/3/2026 (Estimated)

Latest ACRS, LXRX, SNDX, and PAHC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.16-$0.15+$0.01-$0.15$1.32 million$2.00 million
5/7/2026Q1 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million
5/6/2026Q3 2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.72$0.76+$0.04$0.59$367.02 million$383.54 million
4/30/2026Q1 2026
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
-$0.59-$0.48+$0.11-$0.48$69.76 million$64.86 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.481.51%N/A20.60%N/A
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ACRS, LXRX, SNDX, and PAHC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/5/2026
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.121.51%6/3/20266/3/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
4.03
4.03
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.24
18.80
18.77
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.97
3.17
1.26
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
8.26
5.47
5.06

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100139.66 million132.96 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140444.20 million382.01 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2,47540.57 million20.23 millionOptionable
Syndax Pharmaceuticals, Inc. stock logo
SNDX
Syndax Pharmaceuticals
11088.61 million84.36 millionOptionable

Recent News About These Companies

Syndax Pharmaceuticals (SNDX) Gets a Buy from Guggenheim

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$4.34 -0.02 (-0.46%)
Closing price 06/16/2026 04:00 PM Eastern
Extended Trading
$4.34 0.00 (-0.12%)
As of 06/16/2026 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$1.95 -0.01 (-0.51%)
Closing price 06/16/2026 04:00 PM Eastern
Extended Trading
$1.94 -0.01 (-0.31%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$31.87 -0.41 (-1.27%)
Closing price 06/16/2026 04:00 PM Eastern
Extended Trading
$31.90 +0.04 (+0.11%)
As of 06/16/2026 05:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Syndax Pharmaceuticals stock logo

Syndax Pharmaceuticals NASDAQ:SNDX

$18.55 +0.07 (+0.38%)
As of 06/16/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.